Malignant Mesothelioma Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Expected Malignant Mesothelioma Market Size During the Forecast Period?
In recent times, there has been a substantial expansion in the market size of malignant mesothelioma. The projection shows an increase from $2.46 billion in 2024 to $2.63 billion in 2025, representing a compound annual growth rate (CAGR) of 6.8%. This substantial increase during the historical period can be credited to a surge in oncology research funding, an escalation in asbestos-related court lawsuits, an expansion in hospital investments, a growth in the aged population, and the development in AI-powered drug discovery platforms.

The market for malignant mesothelioma is predicted to experience significant expansion in the upcoming years. With a compound annual growth rate (CAGR) of 6.7%, it is expected to reach $3.41 billion by 2029. This predicted growth is thanks to factors such as the increasing popularity of immunotherapy treatments, heightened attention towards personalized medicine, greater use of minimal surgical procedures, rising health care costs, and an increase in clinical trials. Key trends for the forecasted period encompass progress in immunotherapy, personalised medicine, initiatives for early detection, minimally invasive surgical processes, and regulatory authorizations.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22046

What Are the High-Growth Segments in the Malignant Mesothelioma Market?
The malignant mesothelioma market covered in this report is segmented -

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy
2) By Route Of Administration: Oral, Intravenous, Injectable, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
4) By End-User: Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories

Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp

What Key Drivers Are Expected to Influence Future Malignant Mesothelioma Market Growth?
The growth of the malignant mesothelioma market is anticipated to be fueled by the escalating efforts towards clinical research and development. The process involves scientific studies and testing aimed at creating new drugs, treatments, and medical appliances. This entails evaluating the safety, efficacy, and potential side effects of new products via controlled clinical trials. The heightened clinical research and development activities have been spurred on by the increased demand for enhanced medications, particularly in the face of the prevalent chronic illnesses and intricate conditions. These research and development endeavors are pivotal in driving malignant mesothelioma by expediting advancements in diagnostics, treatments, and tailored therapies, encouraging innovative methods that allow for early detection, better survival rates, and the creation of more potent, less intrusive treatment options. In January 2025, for instance, nearly 40% of the US pharmaceutical research budget, about $7 billion annually, was dedicated to clinical trials according to the Anadolu Agency, a Turkey-based state-owned news agency. Consequently, these rising research and development activities are steering the growth of the malignant mesothelioma market forward.

Which Companies Hold the Largest Share Across Different Malignant Mesothelioma Market Segments?
Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center

What Trends Are Driving Growth in The Malignant Mesothelioma Market?
Leading companies in the malignant mesothelioma market are proactive in innovating advanced treatment methods, such as monoclonal antibody treatments, to curb tumor development and enhance the precision of treatment. Essentially, monoclonal antibodies are proteins created in a lab that imitate the body's immune system's capacity to identify and target specific antigens like those found in cancer cells. For example, in November 2023, Ono Pharmaceutical Co. Ltd., a pharmaceutical entity based in Japan, was granted additional approval in Japan for the extension of the use of Opdivo (nivolumab), a human PD-1 monoclonal antibody for treating malignant mesothelioma (excluding malignant pleural mesothelioma). This approval signifies Opdivo's new role as a treatment alternative for this disease, which had no prior standard treatments. Furthermore, the designation of Opdivo as an orphan drug for this indication underlines its potential to meet a critical medical need.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

What Are the Emerging Geographies for The Malignant Mesothelioma Market Growth?
North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Malignant Mesothelioma Market?
2. What is the CAGR expected in the Malignant Mesothelioma Market?
3. What Are the Key Innovations Transforming the Malignant Mesothelioma Industry?
4. Which Region Is Leading the Malignant Mesothelioma Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.